Does Insurance Cover Ozempic and Wegovy in Canada?
Coverage for GLP-1 medications in Canada is fragmented, inconsistent, and actively evolving. Here is the complete picture - and how to maximize your chances of getting covered.
The short answer: it depends. Coverage for GLP-1 weight loss medications in Canada varies significantly by drug, indication, province, and the type of insurance plan you have. Ozempic for diabetes is widely covered; Wegovy for weight management is much less so. Understanding the landscape can save you hundreds of dollars per month.
Coverage at a Glance
| Drug | Indication | Provincial Plans | Private Insurance |
|---|---|---|---|
| Ozempic | Type 2 diabetes | ✅ Covered in most provinces (criteria apply) | ✅ Usually covered for diabetes |
| Ozempic | Weight management (off-label) | ❌ Not covered (no weight indication) | ⚠️ Variable - often denied |
| Wegovy | Weight management | ❌ Not on any provincial formulary | ⚠️ Growing; still inconsistent |
| Mounjaro | Type 2 diabetes | ⚠️ Some coverage with authorization | ⚠️ Variable by plan |
| Rybelsus | Type 2 diabetes | ✅ Covered in several provinces | ✅ Usually covered for diabetes |
Provincial Drug Plans
Canada does not have a national pharmacare program, so drug coverage varies significantly by province. Here is the general picture for GLP-1 medications:
For Type 2 Diabetes (Ozempic/Rybelsus)
Most provincial drug plans cover semaglutide for type 2 diabetes when prescribed on-label and meeting specific clinical criteria. These typically include:
- Established type 2 diabetes diagnosis
- Inadequate glycemic control on first-line medications (often metformin)
- BMI or cardiovascular risk criteria (varies by province)
- Prior authorization or "special authorization" from the prescribing physician
For Weight Management
As of mid-2025, no provincial drug plan in Canada covers Wegovy or any GLP-1 medication specifically for weight management without a comorbid diabetes diagnosis. This is a significant access gap that advocacy groups and medical associations are actively pushing to change.
Private Insurance
Private drug insurance - whether through an employer group benefits plan or individually purchased - is the most likely source of coverage for weight-management GLP-1 use.
Coverage varies enormously by plan. Factors that affect whether your plan covers Wegovy or off-label Ozempic for weight management include:
- Plan formulary: Whether the specific drug is listed on your plan's approved drug list
- Indication requirement: Some plans cover only on-label use; some cover off-label at physician discretion
- Annual or lifetime maximums: Even if covered, many plans have dollar caps (e.g., $1,500/year for drug benefits), which quickly get exhausted at $400/month
- Prior authorization: Most plans require prior authorization for high-cost drugs like GLP-1 medications
The trend is improving: In 2023–2025, several major Canadian benefit plan administrators updated their formularies to include Wegovy for weight management. Plans associated with large employers tend to have broader coverage than smaller group plans.
Find out if you qualify for GLP-1 treatment
Felix matches you with a licensed Canadian provider in minutes - no clinic visit needed.
Prior Authorization: How to Get It
Prior authorization (PA) is the process where your insurer or provincial plan pre-approves coverage before dispensing. It typically requires your physician to submit clinical documentation. Here is how to maximize approval chances:
- Document your clinical picture thoroughly: Ensure your chart includes your BMI, weight history, comorbidities, past weight-loss attempts, and any cardiovascular risk factors. The more clinical detail, the stronger the case.
- Request the right indication: If you have type 2 diabetes, prediabetes, or cardiovascular disease, these comorbidities significantly strengthen a PA request.
- Use your drug plan's specific PA form: Each insurer has its own form. Ask your pharmacy or physician's office for the correct one.
- Ask your physician to emphasize medical necessity: Language like "obesity as a chronic disease requiring pharmacological management" and references to cardiovascular risk reduction are persuasive.
- Request a letter of support: A letter from a specialist (endocrinologist, cardiologist, obesity physician) carries more weight than a GP note alone.
If You Are Denied
A denial is not the end. Most drug plans have a formal appeals process:
- Request the denial in writing with the specific reason - you need to know exactly what criterion was not met.
- Address the specific reason in your appeal - if denied for lack of a comorbidity, document all relevant conditions.
- Involve a specialist: A letter from an endocrinologist or obesity specialist often changes the outcome on appeal.
- Consider a different plan option: If on an employer plan, open enrollment may allow you to switch to a plan with better formulary coverage.
- Use patient support programs (see below) while you appeal.
Manufacturer Patient Support Programs
Both Novo Nordisk and Eli Lilly offer financial assistance programs for Canadians who cannot access coverage:
- Novo Nordisk Care Rx: Supports patients on Ozempic and Wegovy with insurance navigation assistance and, in some cases, co-pay support. Contact through your physician or pharmacist.
- Mounjaro Patient Support (Lilly): Lilly Cares provides co-pay assistance for qualifying patients; eligibility and terms vary.
Ask your prescribing provider or pharmacist to connect you with these programs - they can significantly reduce out-of-pocket costs while you navigate coverage.
Province-by-Province Provincial Plan Coverage
| Province | Public Plan | Ozempic Coverage (Diabetes) | Weight Mgmt Coverage |
|---|---|---|---|
| Ontario | ODB | ✅ With special authorization | ❌ Not covered |
| British Columbia | BC PharmaCare | ✅ On formulary (criteria) | ❌ Not covered |
| Alberta | AB Blue Cross (Seniors/AISH) | ✅ With authorization | ❌ Not covered |
| Quebec | RAMQ | ✅ On formulary | ❌ Not covered |
| Manitoba | Manitoba Pharmacare | ⚠️ Limited; deductible applies | ❌ Not covered |
| Saskatchewan | SK Drug Plan | ✅ With special authorization | ❌ Not covered |
| Nova Scotia | NS Pharmacare | ⚠️ Senior/social assistance only | ❌ Not covered |
| New Brunswick | NB PDP | ✅ With authorization | ❌ Not covered |
| Newfoundland | NL Prescription Drug | ⚠️ Select populations | ❌ Not covered |
| PEI | PEI Pharmacare | ⚠️ Income-based programs | ❌ Not covered |
Frequently Asked Questions
Does my employer benefits plan cover Wegovy?
It depends entirely on your specific plan. Review your benefits booklet for GLP-1 medications or contact your plan administrator. Many major employer plans have added Wegovy coverage in 2023–2025 as obesity medicine evolves.
My plan denied Wegovy - can I still get it?
Yes. You can pay out-of-pocket, appeal the decision, enrol in a manufacturer support program, or - if you have type 2 diabetes - explore whether Ozempic for diabetes is covered instead. Some patients also access coverage under a different clinical justification (e.g., cardiovascular risk reduction following the SELECT trial).
Will national pharmacare cover GLP-1 medications?
The federal government's pharmacare legislation (Bill C-64) is currently focused on diabetes medications and contraceptives. GLP-1 coverage for weight management under a national plan is not imminent as of 2025, though it is an active advocacy issue.